Cytokine-mediated gene therapy for cancer

Annals of Surgical Oncology

Volumn 1, Issue 5, 1994, Pages 436-450

  Miller, Alexander R ^a   McBride, William H ^a   Hunt, Kelly ^a   Economou, James S ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Cytokine; Gene transfer; Protective immunity; Tumor rejection

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR;

ANIMAL; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; IMMUNOLOGY; METHODOLOGY; NEOPLASM; REVIEW;

ANIMAL; CYTOKINES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMAN; INTERFERON TYPE II; INTERFERON-ALPHA; INTERLEUKINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; TUMOR NECROSIS FACTOR;

EID: 0028512286     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1007/BF02303818     Document Type: Review

References (142)

1. An overview of mechanisms responsible for tumor dormancy
2. Principles of cancer biology: tumor immunology
3. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients
4. The antitumor function of tumor necrosis factor (TNF) I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity
5. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk
6. Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response
7. Human renal carcinoma line transfected with interleukin-2 and/or interferon-a gene(s): implications for live cancer vaccines
8. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance
9. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma
10. Vaccination with irradiated tumor cells engineered to secrete murine ganulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
11. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant
12. A new technique for the assay of infectivity of human adenovirus 5 DNA
13. Introduction and expression of DNA molecules in eukaryotic cells by electroporation
14. Transduction of a foreign histocompatibility gene into the arterial wall induces vasculitis
15. Immunotherapy of malignancy by in vivo gene transfer into tumors
16. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice
17. Immunotherapy of malignancy by in vivo gene transfer into tumors
18. Retroviral-mediated gene transfer
19. Somatic gene therapy
20. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer
21. Retrovirus vectors: promise and reality
22. Use of adeno-associated virus as a general transduction vector for mammalian cells
23. Development of adenovirus vectors for the expression of heterologous genes
24. Adenovirus-based expression vectors and recombinant vaccines
25. Interleukin-2: Inception, impact, and implications
26. Overview of biological response modifiers
27. Immunotherapy and gene therapy of cancer
28. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA
29. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity
30. Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2
31. Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunological properties with IL-2
32. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells
33. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells
34. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
35. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene
36. Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2
37. Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor
38. Identification of a T cell-derived B cell growth factor distinct from interleukin 2
39. Regulation of cytolytic T-lymphocyte generation by B-cell stimulatory factor
40. Inter-leukin 4 mediates autocrine growth of helper T cells after antigenic stimulation
41. B-cell stimulatory factor-1/Interleukin 4
42. B cell stimulatory factor 1 (IL-4) enhances the development of cytotoxic T cells from Lyt-2+ resting murine T lymphocytes
43. Interleukin-4 downregulates interleukin-6 production in human peripheral blood mononuclear cells
44. Interleukin-4 down-regulates IL-1 and TNF gene expression in human monocytes
45. Interleukin 4 potentiates the anti-proliferative effects of tumor necrosis factor on various tumor cell lines
46. The cytokine network
47. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma
48. Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells
49. Administration of recombinant IL-4 to humans regulates gene expression, phenotype, and function in circulating monocytes
50. Murine interleukin-4 displays potent anti-tumor activity in vivo
51. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4
52. Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4
53. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4
54. Immunotherapy with cytokine gene-transduced tumor cells: the next wave in gene therapy for cancer
55. An endotoxin-induced serum factor that causes necrosis of tumors
56. Effect of interleukin 2, interferon-g, and mitogens on the production of tumor necrosis factors a and b
57. Tumor necrosis factors: gene structure and biological activities
58. Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A, B antigens in vascular endothelial cells and dermal fibroblasta in vitro
59. Production of tumor necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by phorbol myristate acetate and anti-CD3 antibody
60. Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells
61. Tumor necrosis factors α and β differ in their capacities to generate interleukin 1 release from human endothelial cells
62. Enhancement of antigen-and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-a
63. Cachectin/tumor necrosis factor
64. Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro
65. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages
66. Tumors secreting human TNF/cachectin induce cachexia in mice
67. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer
68. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T cell immunity
69. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha
70. In vivo activity of tumor necrosis factor (TNF) mutants: secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor
71. Modulation of the tumorigenicity of human adenovirus-12-transformed cells by interferon
72. Interferon: a cytotoxic T lymphocyte differentiation signal
73. IL-2 and IFN-γ are two necessary lymphokines in the development of cytotoxic T cells
74. Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity
75. Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by γ-interferon enhances spontaneous and bispecific anti-CD3 X antitumor antibody-directed lymphokine-activated killer cell cytotoxicity
76. HLA-class-I and class-II expression on renal tumor xenografts and the relation to sensitivity for α-IFN, γ-IFN and TNF
77. Interferons
78. Induction by IL 1 and interferon-γ: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1)
79. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review
80. Enhancement of metastatic potential by γ-IFN
81. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells
82. A nonimmunogenic sarcoma transduced with the cDNA for interferon γ elicits CD8 T cells against the wildtype tumor: correlation with antigen presentation capability
83. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity
84. Role of the major histocompatability complex class I antigens in tumor growth and metastasis
85. Reduced tumorigenicity of murine tumor cell secreting γ-interferon is due to nonspecific host responses and is unrelated to class I major histocompatability complex expression
86. Comparative antiproliferative activity in vitro of natural interferons α and β for diploid and transformed human cells
87. Direct antiproliferative effects of recombinant human interferon-a B/D hybrids on human tumor cell lines
88. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo
89. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma
90. Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon
91. Clinical toxicity of interferons in cancer patients: a review
92. a1-Interferon gene transfer into metastatic friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells
93. Interleukin-1 and Interleukin-1 antagonism
94. Pathogenesis of fever
95. There is more than one interleukin-1
96. Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro
97. Interleukin-1 stimulates proliferation of acute myeloblastic leukemia cells by induction of granulocyte-macrophage colony-stimulating factor release
98. Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2
99. Interleukin-1 produced by tumorigenic fibroblasts influences tumor rejection
100. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1
101. Production of interleukin-1a, interleukin-lb and tumor necrosis factor by human mononu-clear cells stimulated with granulocyte-macrophage colony-stimulating factor
102. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1a either spontaneously or following IL-1a gene transfer
103. Interleukin-1 production by transformed fibroblasts. II. Influence on antigen presentation and T-cell-mediated anti-tumor response
104. Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function
105. IFN-β2/IL-6 augments the activity of human natural killer cells
106. IL-6/IFN-β-2 as a circulating hormone: induction by cytokine administration in humans
107. Interleukin-6: an overview
108. Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression
109. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential
110. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells
111. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-b2
112. Effect of interleukin-6 on tumor cell growth in vivo and in vitro
113. Antitumor activity of recombinant interleukin 6 in mice
114. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice
115. Human IL-7: a novel T cell growth factor
116. Interleukin 7 down-regulates fibrosarcoma production of transforming growth factor-β
117. In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor T lymphocytes
118. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity
119. Interleukin 7 induces CD4+ T cell-dependent tumor rejection
120. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo
121. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells
122. Cloning and expression of murine IL-12
123. Interleukin-12. A recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors
124. Interleukin 12 and tumor necrosis factor a are costimulators of intereron γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist
125. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells
126. Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells
127. Antitumor and antimetastatic activity of interleukin-12 against murine tumors
128. Suppressed growth of murine melanoma in vivo with local secretion of interleukin-12 delivered by transfected fibroblasts
129. Factors affecting the transduction of pluripotent hematopoietic stem cells: long-term expression of a human adenosine deaminase gene in mice
130. The panspecific hemopoietin of activated T lymphocytes (interleukin 3)
131. Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism
132. The clinical use of colony stimulating factors
133. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo
134. Implantation of fibroblasts transfected (calcium phosphate) with human granulocyte colony-stimulating factor cDNA into mice as a model of cytokine-supplement gene therapy
135. Interleukin-2 producing fibroblast cell line abrogates tumorigenicity in a murine tumor model: an approach to genetically engineered tumor vaccines
136. Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils
137. Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant products
138. The dendritic cell system and its role in immunogenicity
139. Macrophage activation by granulocyte/macrophage colony stimulating factor
140. Activation of antibody-dependent cell-mediated cytotoxicity of human neutrophils and eosinophils by separate colony-stimulating factors
141. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression